3-(噻吩-2-基)-1H-吡唑-5-羧酸乙酯 | 121195-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(噻吩-2-基)-1H-吡唑-5-羧酸乙酯
• 中文别名: 5-(2-噻吩基)吡唑-3-甲酸乙酯；3-(2-噻吩)-1H-吡唑-5-羧酸乙酯；3-(噻吩-2-基)-1H-吡唑-5-甲酸乙酯
• 英文名称: ethyl-5-(2-thienyl)-1H-pyrazole-3-carboxylate
• 英文别名: ethyl 5-thien-2-yl-1H-pyrazole-3-carboxylate；ethyl 5-thiophen-2-yl-1H-pyrazole-3-carboxylate
• CAS: 121195-03-7
• 化学式: C₁₀H₁₀N₂O₂S
• mdl: MFCD00099767
• 分子量: 222.268
• InChiKey: NTCRDZSJYGZRIE-UHFFFAOYSA-N

物化性质

• 熔点：
  138-140°C
• 沸点：
  430.0±35.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)
• 溶解度：
  17 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  83.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2934999090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332

SDS

Name:	Ethyl 3-(2-thienyl)-1H-pyrazole-5-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	121195-03-7

Section 1 - Chemical Product MSDS Name:Ethyl 3-(2-thienyl)-1H-pyrazole-5-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
121195-03-7	Ethyl 3-(2-thienyl)-1H-pyrazole-5-carb	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 121195-03-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 138 - 140 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10N2O2S
Molecular Weight: 222

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 121195-03-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 3-(2-thienyl)-1H-pyrazole-5-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 121195-03-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 121195-03-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 121195-03-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(噻吩-2-基)-1H-吡唑-5-羧酸乙酯 在 N-氯代丁二酰亚胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 4-chloro-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS
  [FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES

  摘要：

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。

  公开号：

  WO2003105853A1
• 作为产物：
  描述：

  2,4-二氧代-4-(2-噻吩)丁酸乙酯 在 盐酸肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以8.9 g的产率得到3-(噻吩-2-基)-1H-吡唑-5-羧酸乙酯
  参考文献：
  名称：

  The First Example of Azole-Fused Cyclic Anhydride Reacting in the Castagnoli–Cushman Way

  摘要：

  嘌唑并环酸酐首次被用作Castagnoli–Cushman反应的反应物，以极为便捷和迅速的方式生产迄今为止未知的4-氧代-4,5,6,7-四氢嘌唑并[1,5-a]嘌啶-7-羧酸酯。尝试使用吲哚和苯并咪唑类似物实现相同的化学反应失败。

  DOI：

  10.1055/s-0036-1591908

文献信息

• Substituted piperazines
  申请人：ChemoCentryx, Inc.

  公开号：US20040162282A1

  公开（公告）日：2004-08-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且这些化合物在动物炎症测试中进一步得到确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用作竞争性CCR1拮抗剂鉴定的检测中是有用的。
• Haloacetylated Enol Ethers, 19: Synthesis of 3-(2-Thienyl)- and 3-(2-Furyl)-5-trihalomethyl Substituted Azoles
  作者：Alex Flores、Sergio Brondani、Lucas Pizzuti、Marcos Martins、Nilo Zanatta、Helio Bonacorso、Darlene Flores

  DOI：10.1055/s-2005-872140

  日期：——

  Heterocyclization of 1,1,1-trifluoro[chloro]-4-methoxy-4-[2-tienyl]-3-buten-2-one and 1,1,1-trifluoro[chloro]-4-methoxy-4-[2-furyl]-3-buten-2-ones into isoxazoles and pyrazoles derivatives as a new type of trihalomethylated bicyclic heterocycles is reported.

  1,1,1-三氟[氯]-4-甲氧基-4-[2-噻吩基]-3-丁烯-2-酮和1,1,1-三氟[氯]-4-甲氧基-4-的杂环化报道了将[2-呋喃基]-3-丁烯-2-酮转化为异恶唑和吡唑衍生物作为新型三卤甲基化双环杂环。
• Benzimidazole derivatives and their use as KDR kinase protein inhibitors
  申请人：Babin Didier

  公开号：US20050009894A1

  公开（公告）日：2005-01-13

  The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.

  该发明公开和要求具有以下结构的苯并咪唑化合物（I）：其中X为C—R2；Y为C—R2或C—R3；W和Z均为C—R3；R1为选择性取代的芳基、杂环芳基或饱和的5-或6-成员单环杂环基或双环杂环基；A5为H或烷基；或者为该化合物的立体异构体、拉克酸盐、对映异构体或二对映异构体；该化合物的用途为治疗血管增殖障碍、不受控制的血管生成、纤维化障碍、系膜细胞增殖障碍、代谢障碍、过敏、哮喘、血栓形成、神经系统疾病、视网膜病变、银屑病、类风湿性关节炎、糖尿病、肌肉退化、实体肿瘤和癌症的药物组合物包括化合物（I）和一个或多个药用辅料或稀释剂，以及包括化合物（I）和一个或多个抗有丝分裂剂的药物组合物。
• Pyrazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1433788A1

  公开（公告）日：2004-06-30

  The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0；R1；R2；R3；R4；Q；V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在的情况，或者用于治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明涉及式I化合物的制备方法，它们的使用，特别是作为药物活性成分以及含有它们的药物制剂。
• Development of novel androgen receptor antagonists based on the structure of darolutamide
  作者：Qian Xu、Zixiong Zhang、Chenchao Huang、Qiqi Bao、Rongyu Zhang、Meng Wu、Xiaohui Xiao、Xiaoli Han、Xiaoyu Li、Jinming Zhou

  DOI：10.1016/j.bioorg.2022.105829

  日期：2022.7

  antiandrogen because of its unique chemical structure and good activity against androgen receptor (AR). Herein, the structure-activity relationship of ODM-201 was studied, and 37 analogues were synthesized. Half of them exhibited similar or better anti-AR transcriptional activity compared to ODM-201. In addition, the inhibitory activity of compound 28t against the two resistant mutants (AR-F876L and AR-T877A)

  雄激素信号通路在前列腺癌（PCa）的发生发展中发挥着重要作用，而抗雄激素药物是治疗前列腺癌最有效的疗法之一。Darolutamide 4 (ODM-201) 是一种很有前途的第二代抗雄激素药物，因为它具有独特的化学结构和对雄激素受体 (AR) 的良好活性。本文研究了ODM-201的构效关系，合成了37个类似物。与 ODM-201 相比，其中一半表现出相似或更好的抗 AR 转录活性。此外，化合物28t的抑制活性对两种抗性突变体（AR-F876L 和 AR-T877A）的抗性优于 ODM-201。该研究为进一步优化ODM-201和开发抗CRPC药物提供了新线索。